期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

国产奥沙利铂联合羟喜树碱治疗复发性卵巢上皮癌疗效分析

下载PDF
导出
作者 王毅峰 宋文广 范扶民
机构地区 河北医科大学附属唐山市工人医院妇产科 唐山市工人医院放化疗科
出处 《中国煤炭工业医学杂志》 2006年第9期935-936,共2页 Chinese Journal of Coal Industry Medicine
关键词 卵巢肿瘤 复发性 药物疗法 奥沙利铂 羟喜树碱
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1沈铿.复发性卵巢癌的诊断和治疗策略[J].现代妇产科进展,2005,14(3):177-180. 被引量：35
  • 2Pectasides D,Papadopoulou M,Varthalitis J,et al.Paclitaxelin cisplatin or carboplatin-pretreated ovarian cancer.phas Ⅱ study[J].Oncol,1998,55(3):228-234
  • 3Roland T Skeel.Handbook of cancer Chemotherapy[M].6th edition.USA:Lippincott Williams & Wilkins company,2003:305-312
  • 4Gershenson DM.Irinotecan in epithelial ovarian cancer[J].Oncology (Huntingt),2002,16 (Suppl 5):29-31
  • 5Sugiyama T,Ush IJ Ima K,Kamura T.New regimens for the treatment of gynecologic cancers[J].Gan To Kagaku Ryoho,2000,27(3):375-381
  • 6隋凤瑞 薛润清.羟基喜树碱治疗卵巢癌疗效分析[J].中国肿瘤临床,2000,27:172-173.
  • 7苑树俐,马荣,陈曦海.伊立替康联合顺铂治疗复发卵巢癌40例的临床疗效[J].中国新药与临床杂志,2005,24(2):122-125. 被引量：10

二级参考文献10

  • 1[1]VANHOEFER U,HARSTRICK A,KOHNE CH,et al.Phase Ⅰstudy of a weekly schedule of irinotecan,high-dose leucovorin,and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer[J].J Clin Oncol,1999,17(3):907-913.
  • 2[2]DUCREUX M,YCHOU M,SEITZ JF,et al.Irinotecan combined with bolus fluorouracil,continuous infusion fluorouracil,and high-dose leucovorin every two weeks (LV5FUZ regimen):a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colcorectal cancer[J].J Clin Oncol,1999,17(9):2901-2908.
  • 3[3]SALTZ LB,ELFRING GL,MILLER LL.Weekly irinotecan (CPT-11),leucovorin(LV) and fluorouracil is superior to dairly X5LV/FU in patients CPTs with preciously untreated matastatic colorectal cancer(CRC)[J].Proc ASCO,1999,18:233.
  • 4[4]AGRAWAL S,KANDIMALLA ER,YU D,et al.Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides[J].Int J Oncol,2001,18(5):1061-1069.
  • 5[5]TANAKA H,UMEKAWA T,NAGAO K,et al.Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in platinum-and paclitaxel-resistant epithelial ovarian cancer:case reports[J].Eur J Gynaecol Oncol,2003,24(3-4):337-340.
  • 6[6]GERSHENSON DM.Irinotecan in epithelial ovarian cancer[J].Oncology (Huntingt),2002,16(5 Suppl 5):29-31.
  • 7[7]SUGIYAMA T,USHIJIMA K,KAMURA T.New regimens for the treatment of gynecologic cancers[J].Gan To Kagaku Ryoho,2000,27(3):375-381.
  • 8[8]van CUTSEM E,CUNNINGHAM D,TEN BOKKEL HUININK WW,et al.Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-FU[J].Eur J Cancer,1999,35(1),54-59.
  • 9[9]MARKMAN M,ZANOTTI K,WEBSTER K,et al.Toxicity associated with carboplatin/paclitaxel/irinotecan use in advanced ovarian cancer:preliminary analysis[J].Oncology (Huntingt),2003 ,17(5 Suppl 5):34-35.
  • 10[10]-[18] See above

共引文献43

中国煤炭工业医学杂志
2006年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部